EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Genomic Profiling, Induction Response, and Transplant Outcomes in Pediatric Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study

Ana Maria Bicǎ, Andra Daniela Marcu iD, Cristina Georgiana Jercan iD, Iuliana Iordan, Letiția Elena Radu iD, Irina Avramescu iD, Cerasela Jardan, Dumitru Jardan, Onda Tabita Cǎlugǎru, Anda Mocanu, Andrei Colițǎ, Anca Colițǎ iD

International Journal of Molecular Sciences · 28.06.2026 · 27 (13) · 5832

DOI: 10.3390/ijms27135832 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.06.2026. Verfasst von Ana Maria Bicǎ und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pediatric acute myeloid leukemia (AML) is biologically heterogeneous, and genomic profiling increasingly informs risk stratification and treatment. We evaluated the relationship between induction response, genomic risk, transplant allocation, and survival in pediatric AML. We retrospectively analyzed 38 pediatric patients with newly diagnosed AML, treated between 2020 and 2025. Clinical, cytogenetic, molecular, treatment, and outcome data were collected. Genomic alterations were assessed using cytogenetics, fluorescence in situ hybridization (FISH), molecular testing, and next-generation sequencing (NGS). Survival was estimated by Kaplan–Meier analysis, and prognostic factors for event-free survival (EFS) were assessed using univariable Cox regression. This study is exploratory given the limited sample size and should be interpreted accordingly. Complete remission (CR) after the first course of induction was achieved in 25/38 patients (65.8%), partial remission (PR) in 3/38 (7.9%), and refractory disease in 10/38 (26.3%). Twenty-four patients underwent allogeneic hematopoietic stem cell transplantation; 17/24 (70.8%) were alive at last follow-up, with a 2-year overall survival rate of 72.9%. Both induction response and genomic risk stratification showed suggestive associations with outcome; descriptively, induction response showed the strongest prognostic discrimination, with achievement of CR associated with markedly improved survival. High cytogenetic risk and FLT3-ITD were significantly associated with inferior EFS. Post-induction measurable residual disease (MRD) positivity was detected in 16 of 38 patients (42.1%) and was associated with suboptimal induction response; MRD negativity did not uniformly preclude adverse outcomes, particularly in the high-risk genomic subgroup. Genomic profiling refined biological risk and post-remission treatment allocation. Integrated assessment of genomic risk, induction response, and MRD status may improve therapeutic stratification in pediatric AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationHumansRetrospective StudiesChild, PreschoolFemaleChildMaleRemission InductionInfantAdolescentPrognosisGenomicsTreatment OutcomeHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

genomic profilinghematopoietic stem cell transplantationinduction responsenext-generation sequencingpediatric acute myeloid leukemiarisk stratification

Autor:innen und Institutionen

  • Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.
  • Department of Pediatrics and Bone Marrow Transplantation Unit, Fundeni Clinical Institute, 022328 Bucharest, Romania.
  • Department of Bone Marrow Transplant, Fundeni Clinical Institute, 022328 Bucharest, Romania.
  • Department of Hematology Laboratory, Fundeni Clinical Institute, 022328 Bucharest, Romania.
  • Molecular Biology Laboratory, MedLife, 010719 Bucharest, Romania.
  • Department of Hematology, Colțea Hospital, 050098 Bucharest, Romania.

ORCID-Profile: Andra Daniela Marcu, Cristina Georgiana Jercan, Letiția Elena Radu, Irina Avramescu, Anca Colițǎ

Zitieren

APA

Bicǎ, A. M., Marcu, A. D., Jercan, C. G., Iordan, I., Radu, L. E., Avramescu, I., Jardan, C., Jardan, D., Cǎlugǎru, O. T., Mocanu, A., Colițǎ, A., & Colițǎ, A. (2026). Genomic Profiling, Induction Response, and Transplant Outcomes in Pediatric Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study. International Journal of Molecular Sciences, 27(13), 5832. https://doi.org/10.3390/ijms27135832

Vancouver

Bicǎ AM, Marcu AD, Jercan CG, Iordan I, Radu LE, Avramescu I, et al. Genomic Profiling, Induction Response, and Transplant Outcomes in Pediatric Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study. International Journal of Molecular Sciences. 2026;27(13):5832. doi:10.3390/ijms27135832

BibTeX
@article{Bic2026,
  author = {Bicǎ, Ana Maria and Marcu, Andra Daniela and Jercan, Cristina Georgiana and Iordan, Iuliana and Radu, Letiția Elena and Avramescu, Irina and Jardan, Cerasela and Jardan, Dumitru and Cǎlugǎru, Onda Tabita and Mocanu, Anda and Colițǎ, Andrei and Colițǎ, Anca},
  title = {Genomic Profiling, Induction Response, and Transplant Outcomes in Pediatric Acute Myeloid Leukemia: A Single-Center Retrospective Cohort Study},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {13},
  pages = {5832},
  doi = {10.3390/ijms27135832}
}
Kostenlos starten →